» Articles » PMID: 19997482

Identifying Drug Effects Via Pathway Alterations Using an Integer Linear Programming Optimization Formulation on Phosphoproteomic Data

Overview
Specialty Biology
Date 2009 Dec 10
PMID 19997482
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Understanding the mechanisms of cell function and drug action is a major endeavor in the pharmaceutical industry. Drug effects are governed by the intrinsic properties of the drug (i.e., selectivity and potency) and the specific signaling transduction network of the host (i.e., normal vs. diseased cells). Here, we describe an unbiased, phosphoproteomic-based approach to identify drug effects by monitoring drug-induced topology alterations. With our proposed method, drug effects are investigated under diverse stimulations of the signaling network. Starting with a generic pathway made of logical gates, we build a cell-type specific map by constraining it to fit 13 key phopshoprotein signals under 55 experimental conditions. Fitting is performed via an Integer Linear Program (ILP) formulation and solution by standard ILP solvers; a procedure that drastically outperforms previous fitting schemes. Then, knowing the cell's topology, we monitor the same key phosphoprotein signals under the presence of drug and we re-optimize the specific map to reveal drug-induced topology alterations. To prove our case, we make a topology for the hepatocytic cell-line HepG2 and we evaluate the effects of 4 drugs: 3 selective inhibitors for the Epidermal Growth Factor Receptor (EGFR) and a non-selective drug. We confirm effects easily predictable from the drugs' main target (i.e., EGFR inhibitors blocks the EGFR pathway) but we also uncover unanticipated effects due to either drug promiscuity or the cell's specific topology. An interesting finding is that the selective EGFR inhibitor Gefitinib inhibits signaling downstream the Interleukin-1alpha (IL1alpha) pathway; an effect that cannot be extracted from binding affinity-based approaches. Our method represents an unbiased approach to identify drug effects on small to medium size pathways which is scalable to larger topologies with any type of signaling interventions (small molecules, RNAi, etc). The method can reveal drug effects on pathways, the cornerstone for identifying mechanisms of drug's efficacy.

Citing Articles

Functional Profiling of Soft Tissue Sarcoma Using Mechanistic Models.

Paya-Milans M, Pena-Chilet M, Loucera C, Esteban-Medina M, Dopazo J Int J Mol Sci. 2023; 24(19).

PMID: 37834179 PMC: 10572617. DOI: 10.3390/ijms241914732.


Redox integration of signaling and metabolism in a head and neck cancer model of radiation resistance using COSM.

Ji Z, Moore J, Devarie-Baez N, Lewis J, Wu H, Shukla K Front Oncol. 2023; 12:946320.

PMID: 36686772 PMC: 9846845. DOI: 10.3389/fonc.2022.946320.


Discovering potential interactions between rare diseases and COVID-19 by combining mechanistic models of viral infection with statistical modeling.

Lopez-Sanchez M, Loucera C, Pena-Chilet M, Dopazo J Hum Mol Genet. 2022; 31(12):2078-2089.

PMID: 35022696 PMC: 9239744. DOI: 10.1093/hmg/ddac007.


Genome-scale mechanistic modeling of signaling pathways made easy: A bioconductor/cytoscape/web server framework for the analysis of omic data.

Rian K, Hidalgo M, Cubuk C, Falco M, Loucera C, Esteban-Medina M Comput Struct Biotechnol J. 2021; 19:2968-2978.

PMID: 34136096 PMC: 8170118. DOI: 10.1016/j.csbj.2021.05.022.


Signal transduction pathways involved in dopamine D receptor-evoked emesis in the least shrew (Cryptotis parva).

Belkacemi L, Zhong W, Darmani N Auton Neurosci. 2021; 233:102807.

PMID: 33865060 PMC: 8154667. DOI: 10.1016/j.autneu.2021.102807.


References
1.
Daub H, Olsen J, Bairlein M, Gnad F, Oppermann F, Korner R . Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell. 2008; 31(3):438-48. DOI: 10.1016/j.molcel.2008.07.007. View

2.
Baselga J, Averbuch S . ZD1839 ('Iressa') as an anticancer agent. Drugs. 2000; 60 Suppl 1:33-40; discussion 41-2. DOI: 10.2165/00003495-200060001-00004. View

3.
Chaparro M, Gonzalez Moreno L, Trapero-Marugan M, Medina J, Moreno-Otero R . Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther. 2008; 28(11-12):1269-77. DOI: 10.1111/j.1365-2036.2008.03857.x. View

4.
Samaga R, Saez-Rodriguez J, Alexopoulos L, Sorger P, Klamt S . The logic of EGFR/ErbB signaling: theoretical properties and analysis of high-throughput data. PLoS Comput Biol. 2009; 5(8):e1000438. PMC: 2710522. DOI: 10.1371/journal.pcbi.1000438. View

5.
Mendoza L, Xenarios I . A method for the generation of standardized qualitative dynamical systems of regulatory networks. Theor Biol Med Model. 2006; 3:13. PMC: 1440308. DOI: 10.1186/1742-4682-3-13. View